S P R Romaine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
S P R Romaine has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
A J Balmforth
Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK
1 shared publication- Alistair S. Hall
Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds University, Leeds, United Kingdom
1 shared publication K M Bailey
Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK
1 shared publication
Latest Publications
- 3 November 2009
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 10 (1) , 1-11
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of coronary artery disease. Despite this, there is wide inter-individual variability in response to statin therapy, in terms of both lipid-lowering and adverse drug reactions. The major site of statin action is within hepatocytes and recent interest has focussed on genetic variation in hepatic influx and efflux transporters for their potential to explain these differences. In this review we explore current literature regarding the pharmacokinetic and pharmacodynamic influence of the common c.388A>G and c.521T>C single-nucleotide polymorphisms (SNPs) within the solute carrier organic anion transporter 1B1 (SLCO1B1) gene, encoding the organic anion transporter polypeptide 1B1 (OATP1B1) influx transporter. We discuss their potential to predict the efficacy of statin therapy and the likelihood that patients will experience adverse effects.
- 3 November 2009
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 10 (1) , 1-11
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of coronary artery disease. Despite this, there is wide inter-individual variability in response to statin therapy, in terms of both lipid-lowering and adverse drug reactions. The major site of statin action is within hepatocytes and recent interest has focussed on genetic variation in hepatic influx and efflux transporters for their potential to explain these differences. In this review we explore current literature regarding the pharmacokinetic and pharmacodynamic influence of the common c.388A>G and c.521T>C single-nucleotide polymorphisms (SNPs) within the solute carrier organic anion transporter 1B1 (SLCO1B1) gene, encoding the organic anion transporter polypeptide 1B1 (OATP1B1) influx transporter. We discuss their potential to predict the efficacy of statin therapy and the likelihood that patients will experience adverse effects.